Action Argen X - ARGX

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

581,00

Prix Achat

580,80

Prix Vente

581,20

Volume échangé

28 763

575,00 Fourchette du Jour 595,00

322,50 Plage de 52 semaines 658,00

Cap du marché

37,868B

Clôture Veille

592,20

Ouverture

594,80

Dernière Transaction

581

Dernière heure de transaction

16:21:24

Volume financier

VWAP

Volume moyen (3 m)

63 693

Actions en circulation

65 178 000

Rendement du Dividende

Ratio Cours sur Bénéfices

45,05

Bénéfice par action (BPA)

12,78

Chiffre d'affairess

2,25B

Bénéfice net

833,04M

Secteur

Coml Physical, Biologcl Resh

Industrie

Coml Physical, Biologcl Resh

Site Web

www.argenx.com

Siège social

Amsterdam, North Holland, Nld

Fondé

Argen X SE est coté dans le secteur Coml Physical, Biologcl Resh de la Euronext avec le ticker ARGX. Le dernier cours de clôture d'Argen X était de 592,20 €. Au cours de la dernière année, les actions de Argen X ont été négociées dans une fourchette de prix de 322,50 € à 658,00 €.

Argen X compte actuellement 65 178 000 actions en circulation. La capitalisation boursière d'Argen X est de 38,60 € milliard. Argen X a un ratio cours/bénéfice (ratio PE) de 45.05.

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP...

argenx to Present at TD Cowen 45th Annual Healthcare Conference

February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Highlights 2025 Strategic Priorities

Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in...

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-35	-5.68181818182	616	625.8	575	120912	597.71273682	DE
4	-66	-10.200927357	647	651.8	575	69346	607.88609245	DE
12	0.8	0.137883488452	580.2	658	575	63693	617.31096309	DE
26	93	19.0573770492	488	658	456.3	61809	568.6882543	DE
52	223.7	62.608452281	357.3	658	322.5	60364	480.77763813	DE
156	344	145.147679325	237	658	231.8	64665	400.97056848	DE
260	447.6	335.532233883	133.4	658	93.05	72593	319.34388141	DE

ARGX - Frequently Asked Questions (FAQ)

What is the current Argen X share price?

The current share price of Argen X is 581,00 €

How many Argen X shares are in issue?

Argen X has 65 178 000 shares in issue

What is the market cap of Argen X?

The market capitalisation of Argen X is EUR 38,6B

What is the 1 year trading range for Argen X share price?

Argen X has traded in the range of 322,50 € to 658,00 € during the past year

What is the PE ratio of Argen X?

The price to earnings ratio of Argen X is 45,05

What is the cash to sales ratio of Argen X?

The cash to sales ratio of Argen X is 16,66

What is the reporting currency for Argen X?

Argen X reports financial results in USD

What is the latest annual turnover for Argen X?

The latest annual turnover of Argen X is USD 2,25B

What is the latest annual profit for Argen X?

The latest annual profit of Argen X is USD 833,04M

What is the registered address of Argen X?

The registered address for Argen X is LAARDERHOOGTWEG 25, AMSTERDAM, NORTH HOLLAND, 1101 EB

What is the Argen X website address?

The website address for Argen X is www.argenx.com

Which industry sector does Argen X operate in?

Argen X operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
TDBSTonner Drones	0,003 € (200,00%)	40,59M
DMSBSDiagnostic Medical Systems	0,008 € (100,00%)	3k
ALTDTonner Drones	0,0268 € (88,73%)	169,92M
NEGDSNetmedia Group DS	0,0003 € (50,00%)	97,1k
LATLatecoere	0,018 € (46,34%)	160,77M
LUDSLucibel DS	0,0009 € (-35,71%)	13,75k
ALALOAcheterLouerFR	0,0031 € (-26,19%)	30,28M
ALMASMastrad	0,024 € (-22,58%)	4,54M
ALADOAdomos	0,202 € (-22,34%)	20,11k
ALTROTronic s Microsystems	3,64 € (-19,11%)	1
ATOAtos SE	0,005 € (19,05%)	5,94B
ALCYBCybergun	0,0001 € (0,00%)	299,87M
ALTDTonner Drones	0,0268 € (88,73%)	169,92M
LATLatecoere	0,018 € (46,34%)	160,77M
ALEUPEuroplasma	0,0113 € (7,62%)	67,24M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Argen X SE (ARGX)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Argen X SE

ARGX Dernières nouvelles

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx to Participate at Upcoming Investor Conferences

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

ARGX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Argen X SE (ARGX) Cours

Argen X SE (ARGX)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Argen X SE

ARGX Dernières nouvelles

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

argenx to Participate at Upcoming Investor Conferences

argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

argenx Highlights 2025 Strategic Priorities

argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

ARGX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités